Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Gemcitabine + Itacitinib + Nab-paclitaxel||Phase Ib/II||Actionable||In a Phase Ib/II trial, Itacitinib (INCB039110) in combination with nab-paclitaxel and gemcitabine demonstrated safety and preliminary efficacy, resulted in an overall response rate of 24% (13/55, all partial responses) in patients with advanced solid tumors (PMID: 30115734; NCT01858883).||30115734|